CL2011000124A1 - Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer. - Google Patents
Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer.Info
- Publication number
- CL2011000124A1 CL2011000124A1 CL2011000124A CL2011000124A CL2011000124A1 CL 2011000124 A1 CL2011000124 A1 CL 2011000124A1 CL 2011000124 A CL2011000124 A CL 2011000124A CL 2011000124 A CL2011000124 A CL 2011000124A CL 2011000124 A1 CL2011000124 A1 CL 2011000124A1
- Authority
- CL
- Chile
- Prior art keywords
- protein kinase
- raf
- cancer
- treatment
- pyrazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REVELAN LOS DERIVADOS DE 3,4-DIARILPIRAZOL DE LA FÓRMULA (I), COMO DEFINIDO EN LA ESPECIFICACIÓN, Y LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE ELLOS, Y LAS COMPOSICIONES FARMACÉUTICAS QUE LAS COMPRENDEN; LOS COMPUESTOS DE LA INVENCIÓN PUEDEN SER ÚTILES, EN TERAPIA, EN EL TRATAMIENTO DE LAS ENFERMEDADES ASOCIADAS CON UNA ACTIVIDAD DE PROTEÍNA QUINASA DESREGULADA, COMO EL CÁNCER.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08161076 | 2008-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011000124A1 true CL2011000124A1 (es) | 2011-05-06 |
Family
ID=41059486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000124A CL2011000124A1 (es) | 2008-07-24 | 2011-01-20 | Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer. |
Country Status (20)
Country | Link |
---|---|
US (2) | US8541575B2 (es) |
EP (1) | EP2324008B1 (es) |
JP (1) | JP5385382B2 (es) |
CN (1) | CN102105459B (es) |
AT (1) | ATE557015T1 (es) |
AU (1) | AU2009273197B2 (es) |
BR (1) | BRPI0916356B1 (es) |
CA (1) | CA2731146C (es) |
CL (1) | CL2011000124A1 (es) |
CY (1) | CY1117667T1 (es) |
DK (1) | DK2324008T3 (es) |
EA (1) | EA019722B1 (es) |
ES (1) | ES2386408T3 (es) |
HK (1) | HK1157337A1 (es) |
HR (1) | HRP20120577T1 (es) |
MX (1) | MX2011000738A (es) |
PL (1) | PL2324008T3 (es) |
PT (1) | PT2324008E (es) |
SI (1) | SI2324008T1 (es) |
WO (1) | WO2010010154A1 (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2008001943A1 (es) | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
PL2324008T3 (pl) * | 2008-07-24 | 2012-09-28 | Nerviano Medical Sciences Srl | 3,4-diarylopirazole jako inhibitory kinazy białkowej |
UY32146A (es) | 2008-09-29 | 2010-04-30 | Boehringer Ingelheim Int | Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos |
JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
CN104958294A (zh) | 2010-01-27 | 2015-10-07 | 内尔维安诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物 |
JP5871897B2 (ja) | 2010-03-26 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジルトリアゾール |
EP2552905B1 (en) | 2010-03-26 | 2016-10-05 | Boehringer Ingelheim International GmbH | B-Raf kinase inhibitors |
AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
US20130096149A1 (en) * | 2010-06-25 | 2013-04-18 | Novartis Ag | Heteroaryl compounds and compositions as protein kinase inhibitors |
EP2601185B1 (en) * | 2010-08-03 | 2015-10-07 | Nerviano Medical Sciences S.r.l. | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
TWI480276B (zh) * | 2010-08-27 | 2015-04-11 | Irm Llc | 作為蛋白質激酶抑制劑之化合物及組合物 |
US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
SG192126A1 (en) * | 2011-01-25 | 2013-09-30 | Univ Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
US9199979B2 (en) | 2011-02-24 | 2015-12-01 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
KR101298651B1 (ko) * | 2011-03-16 | 2013-08-21 | 연세대학교 산학협력단 | 효능이 강화된 혈관신생 억제용 약제학적 조성물 |
JP6042896B2 (ja) | 2011-10-06 | 2016-12-14 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 殺菌剤としての複素環ピリ(ミ)ジニルピラゾール |
IN2014CN02475A (es) | 2011-10-06 | 2015-06-19 | Bayer Ip Gmbh | |
RU2622015C2 (ru) | 2011-11-11 | 2017-06-08 | Новартис Аг | Способ лечения пролиферативного заболевания |
CA2856406C (en) | 2011-11-23 | 2020-06-23 | Novartis Ag | Pharmaceutical formulations |
JP6178861B2 (ja) | 2012-11-02 | 2017-08-09 | ファイザー・インク | ブルトン型チロシンキナーゼ阻害剤 |
SG11201505525UA (en) | 2013-01-16 | 2015-08-28 | Univ Michigan | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
ES2918924T3 (es) | 2015-04-01 | 2022-07-21 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
CA2993304C (en) * | 2015-08-03 | 2021-06-22 | Glenmark Pharmaceuticals S.A. | Novel compounds as ror gamma modulators |
EA201890730A1 (ru) | 2015-09-16 | 2018-10-31 | Локсо Онколоджи, Инк. | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования |
EA035132B1 (ru) * | 2015-12-16 | 2020-04-30 | Локсо Онколоджи, Инк. | Соединения, которые можно применять в качестве ингибиторов киназы |
RU2759669C2 (ru) | 2016-06-03 | 2021-11-16 | Аррэй Байофарма Инк. | Фармацевтические комбинации |
BR112019005046A2 (pt) | 2016-09-19 | 2019-06-18 | Novartis Ag | combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk |
CN106883266B (zh) * | 2017-01-23 | 2020-03-17 | 江苏七洲绿色化工股份有限公司 | 一种1-(4-氯苯基)-2-环丙基-1-丙酮的制备方法及其中间体 |
WO2019081485A1 (de) | 2017-10-26 | 2019-05-02 | Bayer Cropscience Aktiengesellschaft | Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
WO2019081477A1 (de) | 2017-10-26 | 2019-05-02 | Bayer Cropscience Aktiengesellschaft | Substituierte pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
EP3870177A1 (en) * | 2018-10-26 | 2021-09-01 | Arrien Pharmaceuticals LLC | Pyrazolyl compounds and methods of use thereof |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
CA3142286A1 (en) | 2019-06-03 | 2020-12-10 | Bayer Aktiengesellschaft | 1-phenyl-5-azinyl pyrazolyl-3-oxyalkyl acids and their use for controlling undesired plant growth |
WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
KR102323820B1 (ko) * | 2019-10-31 | 2021-11-08 | 한국화학연구원 | 돌연변이형 idh 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
CN112979613B (zh) * | 2019-12-16 | 2022-04-26 | 四川大学华西医院 | 2-(1h-吡唑-3-基)吡啶衍生物及其制备方法和用途 |
EP4075979A1 (de) | 2019-12-19 | 2022-10-26 | Bayer Aktiengesellschaft | 1,5-diphenylpyrazolyl-3-oxyalkylsäuren und 1-phenyl-5-thienylpyrazolyl-3-oxyalkylsäuren und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums |
WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
CN115003656A (zh) | 2020-01-31 | 2022-09-02 | 拜耳公司 | [(1,4,5-三取代1h-吡唑-3-基)硫烷基]乙酸衍生物和其盐及其作为活性除草成分的用途 |
WO2021202900A1 (en) * | 2020-04-02 | 2021-10-07 | Plexxikon Inc. | 1,6-naphthyridine compounds and methods for csk modulation and indications therefor |
BR112022021901A2 (pt) | 2020-04-29 | 2023-01-17 | Bayer Ag | Ácidos de 1-pirazinilpirazolil-3-oxialquila e seus derivados e seu uso para controle de crescimento indesejado de planta |
CN116368129A (zh) | 2020-10-23 | 2023-06-30 | 拜耳公司 | 1-(吡啶基)-5-吖嗪基吡唑衍生物及其用于控制有害的植物生长的用途 |
IL302359A (en) * | 2020-10-30 | 2023-06-01 | Novartis Ag | New crystalline forms of the KRAS G12C inhibitor compound |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
IL309609A (en) | 2021-06-25 | 2024-02-01 | Bayer Ag | (5,4,1-trisubstituted-1H-pyrazol-3-yl)oxy-2-alkoxy alkyl acids and their derivatives, their salts and their use as herbicides |
WO2023091873A1 (en) * | 2021-11-19 | 2023-05-25 | The Board Of Trustees Of The University Of Illinois | Gram-negative specific antibiotics sparing effect on gut microbiome |
CA3240969A1 (en) | 2021-12-01 | 2023-06-08 | Bayer Aktiengesellschaft | (1,4,5-trisubstituted 1h-pyrazole-3-yl)oxy-2-alkylthioalkyl acids and -alkyl acid derivatives, salts thereof and use thereof as active herbicidal ingredients |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
WO2024078871A1 (de) | 2022-10-14 | 2024-04-18 | Bayer Aktiengesellschaft | 1-pyridyl-5-phenylpyrazolyl-3-oxy- und -3-thioalkylsäuren und derivate und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP1246A (en) | 1997-05-22 | 2004-02-07 | Searle & Co | Substituted pyrazoles as p38 Kinase inhibitors. |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
JP4399265B2 (ja) | 2001-12-21 | 2010-01-13 | ヴァーナリス(ケンブリッジ)リミテッド | 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
KR20060127032A (ko) * | 2004-01-09 | 2006-12-11 | 노파르티스 아게 | Igf―ir 억제제로서의페닐-[4-(3-페닐-1h-피라졸-4-일)-피리미딘-2-일]-아민유도체 |
US20080242667A1 (en) | 2005-08-26 | 2008-10-02 | Smithkline Beecham Corporation | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases |
EP2024353A2 (en) * | 2006-03-16 | 2009-02-18 | Pfizer Products Inc. | Pyrazole compounds |
EP2057146A1 (en) * | 2006-10-02 | 2009-05-13 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
PL2324008T3 (pl) * | 2008-07-24 | 2012-09-28 | Nerviano Medical Sciences Srl | 3,4-diarylopirazole jako inhibitory kinazy białkowej |
CN104958294A (zh) * | 2010-01-27 | 2015-10-07 | 内尔维安诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物 |
EP2601185B1 (en) | 2010-08-03 | 2015-10-07 | Nerviano Medical Sciences S.r.l. | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
-
2009
- 2009-07-23 PL PL09780990T patent/PL2324008T3/pl unknown
- 2009-07-23 SI SI200930286T patent/SI2324008T1/sl unknown
- 2009-07-23 BR BRPI0916356-5A patent/BRPI0916356B1/pt active IP Right Grant
- 2009-07-23 MX MX2011000738A patent/MX2011000738A/es active IP Right Grant
- 2009-07-23 CN CN200980128629.1A patent/CN102105459B/zh active Active
- 2009-07-23 EP EP09780990A patent/EP2324008B1/en active Active
- 2009-07-23 US US13/054,853 patent/US8541575B2/en active Active
- 2009-07-23 EA EA201170249A patent/EA019722B1/ru not_active IP Right Cessation
- 2009-07-23 DK DK09780990.9T patent/DK2324008T3/da active
- 2009-07-23 JP JP2011519176A patent/JP5385382B2/ja active Active
- 2009-07-23 PT PT09780990T patent/PT2324008E/pt unknown
- 2009-07-23 ES ES09780990T patent/ES2386408T3/es active Active
- 2009-07-23 WO PCT/EP2009/059506 patent/WO2010010154A1/en active Application Filing
- 2009-07-23 CA CA2731146A patent/CA2731146C/en active Active
- 2009-07-23 AU AU2009273197A patent/AU2009273197B2/en active Active
- 2009-07-23 AT AT09780990T patent/ATE557015T1/de active
-
2011
- 2011-01-20 CL CL2011000124A patent/CL2011000124A1/es unknown
- 2011-10-28 HK HK11111670.1A patent/HK1157337A1/xx unknown
-
2012
- 2012-07-12 HR HRP20120577AT patent/HRP20120577T1/hr unknown
- 2012-07-13 CY CY20121100628T patent/CY1117667T1/el unknown
-
2013
- 2013-08-20 US US13/970,854 patent/US8946250B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP5385382B2 (ja) | 2014-01-08 |
ATE557015T1 (de) | 2012-05-15 |
SI2324008T1 (sl) | 2012-08-31 |
HRP20120577T1 (hr) | 2012-08-31 |
US20110144068A1 (en) | 2011-06-16 |
MX2011000738A (es) | 2011-02-23 |
PL2324008T3 (pl) | 2012-09-28 |
US8946250B2 (en) | 2015-02-03 |
ES2386408T3 (es) | 2012-08-20 |
CN102105459B (zh) | 2014-09-10 |
EA019722B1 (ru) | 2014-05-30 |
AU2009273197B2 (en) | 2014-01-16 |
EA201170249A1 (ru) | 2011-10-31 |
AU2009273197A2 (en) | 2011-03-10 |
CN102105459A (zh) | 2011-06-22 |
DK2324008T3 (da) | 2012-07-23 |
EP2324008A1 (en) | 2011-05-25 |
CA2731146C (en) | 2016-05-03 |
AU2009273197A1 (en) | 2010-01-28 |
HK1157337A1 (es) | 2012-06-29 |
CA2731146A1 (en) | 2010-01-28 |
BRPI0916356B1 (pt) | 2022-08-23 |
CY1117667T1 (el) | 2017-05-17 |
PT2324008E (pt) | 2012-06-25 |
US20140005150A1 (en) | 2014-01-02 |
WO2010010154A1 (en) | 2010-01-28 |
EP2324008B1 (en) | 2012-05-09 |
US8541575B2 (en) | 2013-09-24 |
BRPI0916356A2 (es) | 2018-08-21 |
JP2011528698A (ja) | 2011-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011000124A1 (es) | Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
TW200833693A (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
WO2009071480A3 (en) | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors | |
PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
MX2009006401A (es) | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. | |
UA94097C2 (ru) | Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ | |
EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
MX2010003927A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b. | |
MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
WO2007125331A3 (en) | Amino-ethyl-amino-aryl (aeaa) compounds and their use | |
BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação | |
BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
MX2009011576A (es) | Nuevos derivados de 4,8-difenil-poliazanaftaleno. | |
ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
ATE496899T1 (de) | Tetrahydro- und dihydrochinazolinone | |
CU20060152A7 (es) | Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa | |
CU23566B7 (es) | Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa |